• Discovery slows down muscular dystrophy

    From ScienceDaily@1:317/3 to All on Wed May 24 22:30:30 2023
    Discovery slows down muscular dystrophy
    University of Houston researchers target protein that can slow disease progression, improve muscle function

    Date:
    May 24, 2023
    Source:
    University of Houston
    Summary:
    A research team has discovered that by manipulating a certain
    protein in the immune system they can slow down disease progression
    and improve muscle function in Duchenne muscular dystrophy.


    Facebook Twitter Pinterest LinkedIN Email

    ==========================================================================
    FULL STORY ==========================================================================
    A team of researchers at the University of Houston College of Pharmacy is reporting that by manipulating TAK1, a signaling protein that plays an important role in development of the immune system, they can slow down
    disease progression and improve muscle function in Duchenne muscular
    dystrophy (DMD).

    DMD, caused by mutations in dystrophin gene, is an inheritable
    neuromuscular disorder that occurs in one out of 3,600 male births. DMD patients undergo severe muscle wasting, inability to walk and eventually
    death in their early thirties due to respiratory failure. The disease is
    marked by an inflammatory response and death of muscle fibers. Eventually,
    the muscle fibers are replaced with fat and fibrotic tissue that causes
    severe muscle weakness.

    "Our results suggest that TAK1 (transforming growth factor b-activated
    kinase1) is a regulator of skeletal muscle mass. By specifically
    targeting this protein, we can suppress the death of muscle fibers,
    known as myonecrosis, and slow down disease progression in DMD," said
    Ashok Kumar, Else and Philip Hargrove Endowed Professor and chair,
    Department of Pharmacological and Pharmaceutical Sciences, whose results
    were published in JCI Insight. "Our research shows that activating TAK1
    can stimulate myofiber growth in a model of DMD, with no negative impact
    on muscle health." In a previous breakthrough, Kumar's team uncovered
    a surprising fact: TAK1 is essential for maintaining skeletal muscle
    mass and that activating TAK1 beyond normal levels can enhance skeletal
    muscle growth.

    For this research, supported by the National Institutes of Health,
    the team designed experiments to reduce or augment the levels of TAK1
    protein in skeletal muscle at different stages of disease progression.

    "Our experiments demonstrate that depletion of TAK1 activity during peak necrotic phase followed by re-introduction of TAK1 at post-necrotic phase
    leads to substantial improvement in muscle pathology," said Anirban Roy, research assistant professor.

    The current standard of care for DMD is focused on reducing inflammation
    with corticosteroids, which modestly reduces disease progression, but
    has serious side effects.

    "Accumulating evidence suggests that regulation of immune response,
    autophagy, and metabolism along with gene correction therapy can be
    promising approaches to slow down disease progression in DMD patients,"
    said Roy.

    * RELATED_TOPICS
    o Health_&_Medicine
    # Muscular_Dystrophy # Fibromyalgia # Fitness #
    Chronic_Illness # Joint_Pain # Neuropathy # Healthy_Aging
    # Human_Biology
    * RELATED_TERMS
    o Immune_system o AIDS o Protein o Physical_exercise o Meat
    o Blood_vessel o Botulinum_toxin_(cosmetic_treatment) o Artery

    ========================================================================== Story Source: Materials provided by University_of_Houston. Original
    written by Laurie Fickman. Note: Content may be edited for style and
    length.


    ========================================================================== Journal Reference:
    1. Anirban Roy, Tatiana E. Koike, Aniket S. Joshi, Meiricris Tomaz
    da Silva,
    Kavya Mathukumalli, Mingfu Wu, Ashok Kumar. Targeted regulation
    of TAK1 counteracts dystrophinopathy in a DMD mouse model. JCI
    Insight, 2023; 8 (10) DOI: 10.1172/jci.insight.164768 ==========================================================================

    Link to news story: https://www.sciencedaily.com/releases/2023/05/230524181848.htm

    --- up 1 year, 12 weeks, 2 days, 10 hours, 50 minutes
    * Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)